Syndax Pharmaceuticals
SNDX
121 hedge funds and large institutions have $1.06B invested in Syndax Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 48 increasing their positions, 36 reducing their positions, and 24 closing their positions.
909% more call options, than puts
Call options by funds: $3.85M | Put options by funds: $381K
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
33% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 36
12% more capital invested
Capital invested by funds: $948M → $1.06B (+$114M)
0.97% less ownership
Funds ownership: 99.19% → 98.21% (-0.97%)
11% less funds holding
Funds holding: 136 → 121 (-15)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.9M |
| 2 |
DM
Deerfield Management
New York
|
+$18.5M |
| 3 |
EP
Eversept Partners
New York
|
+$16.6M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.4M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$9.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$24.4M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$20.2M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$8.43M |
| 4 |
Morgan Stanley
New York
|
-$6.76M |
| 5 |
Millennium Management
New York
|
-$6.69M |
SNDX Hedge Fund Activity: Q2 2022 in Review
121 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2022, worth a combined $1.06B — up 12% from $948M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of SNDX and 13 opened new positions — a net loss of 11 holders — while 36 trimmed existing stakes and 48 added.
The largest buyer was Wellington Management Group, adding an estimated $22.9M. The largest seller was PFM Health Sciences, cutting an estimated $24.4M.
- 121 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2022, down from 136 in Q1 2022.
- Funds reported $1.06B of Syndax Pharmaceuticals stock for Q2 2022, up 12% quarter-over-quarter.
- 13 funds opened new Syndax Pharmaceuticals positions in Q2 2022 and 24 closed out, a net change of -11 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2022 was Wellington Management Group, an estimated $22.9M added.
- The largest Syndax Pharmaceuticals seller in Q2 2022 was PFM Health Sciences, an estimated $24.4M sold.
Based on aggregated 13F filings for Q2 2022.